« Back
Home /
Ulixertinib

Ulixertinib

Item no.	HY-15816-5mg
Manufacturer	MedChem Express
CASRN	869886-67-9
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 200 mg 50 mg 5 mg
Category	Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.95
Formula	C21H22Cl2N4O2
Citations	ACS Comb Sci. 2019 Dec 9;21(12):805-816.<br/>Adv Sci (Weinh). 2022 Oct;9(30):e2200717.<br/>Biomed Chromatogr. 2020 Oct;34(10):e4923.<br/>Cancer Biol Ther. 2022 Jan 9;1-14.<br/>Cancer. 2020 Mar 15;126(6):1339-1350.<br/>Cancers (Basel). 2022 Feb 14;14(4):954.<br/>Cancers (Basel). 2022 Mar 19;14(6):1575.<br/>Cell Death Differ. 2024 May 2.<br/>Cell Death Discov. 2022 Aug 17;8(1):365.<br/>Cell Rep. 2021 Dec 28;37(13):110174.<br/>Dev Cell. 2020 Sep 14;54(5):608-623.e5.<br/>Front Cell Dev Biol. 2018 Sep 25;6:111.<br/>Innate Immun. 2020 Aug;26(6):505-513.<br/>J Gastroenterol. 2024 Apr 29.<br/>J Invest Dermatol. 2020 Sep 9;S0022-202X(20)32055-8.<br/>Matrix Biol. 5 August 2022.<br/>Mol Cell Endocrinol. 2023 Dec 24:582:112140.<br/>Nat Commun. 2022 Jul 14;13(1):4078.<br/>Nat Commun. 2023 May 19;14(1):2859.<br/>Nat Commun. 2023 Nov 2;14(1):6997.<br/>Pharmacol Res. 2023 Oct 14:197:106955.<br/>Platelets. 2024 Dec;35(1):2354833.<br/>Research Square Print. 2023 Feb 22.<br/>Sci Adv. 2023 Nov 15;9(46):eadi5921.<br/>Sci Transl Med. 2021 Jan 27;13(578):eaba7308.<br/>Theranostics. 2022 Oct 3;12(16):7051-7066.<br/>Ulm University. Molecular Medicine Ulm. 2021 Mar.<br/>Cancer Res. 2024 Mar 19.<br/>[1]Ward RA, et al. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. J Med Chem. 2015 Jun 11;58(11):4790-801.<br/>[2]Kumar R, et al. Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. J Pharm Biomed Anal. 2016 Jun 5;125:140-4.<br/>[3]Changwen Ning, et al. Targeting ERK Enhances the Cytotoxic Effect of the Novel PI3K and mTOR Dual Inhibitor VS-5584 in Preclinical Models of Pancreatic Cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311.
Smiles	O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[C@@H](C3=CC=CC(Cl)=C3)CO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BVD-523; VRT752271
Available
Product Description	Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of [1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	433.33
Clinical Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Target	ERK
Manufacturers Target	ERK
Isoform	ERK1; ERK2
Manufacturers Pathway	MAPK/ERK Pathway; Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15816-5mg-safety-datasheet.pdf